Literature DB >> 35381787

Predictive significance of inflammatory indexes in metastatic nonsmall cell lung cancer patients treated with platinum-doublet chemotherapy.

Mesut Yilmaz1, Ahmet Baran2, Merve Korkmaz Yilmaz3.   

Abstract

Introduction: Lung cancer is the leading cause of cancer-related deaths, worldwide. Despite immune checkpoint inhibitors and targeted therapy have revolutionized the treatment of metastatic nonsmall cell lung cancer (NSCLC), a significant proportion of patients are still treated with platinum-based chemotherapy. It is widely noticed that systemic inflammation plays an important role in the development and progression of many solid tumors. In this study, we aimed to analyze the predictive role of the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and prognostic nutritional index (PNI) in patients with advanced NSCLC treated with first-line platinum-doublet chemotherapy.
Methods: We retrospectively collected data of patients treated with first-line therapy for metastatic NSCLC. All patients were treated with first-line platinum-doublet chemotherapy. The patients were grouped based on the median values of SII, PNI, and NLR. The Mann-Whitney U test was used for comparisons between groups.
Results: The chemotherapy response rate (RR) was 75% in all patients. RR is statistically significantly lower in high SII, low PNI, and high NLR groups. Conclusions: High inflammatory indexes in metastatic NSCLC patients who were treated with platinum-doublet chemotherapy are related to low chemotherapy RR.

Entities:  

Keywords:  Inflammatory indexes; lung cancer; neutrophil-to-lymphocyte ratio; prognostic nutritional index; systemic immune-inflammation index

Mesh:

Year:  2022        PMID: 35381787     DOI: 10.4103/jcrt.jcrt_1902_20

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  1 in total

1.  Association between SII and hepatic steatosis and liver fibrosis: A population-based study.

Authors:  Ruijie Xie; Mengde Xiao; Lihong Li; Nengqian Ma; Mingjiang Liu; Xiongjie Huang; Qianlong Liu; Ya Zhang
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.